Hangzhou Diagens Biotechnology Co., Ltd.
杭州德適生物科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2526)

PROPOSED ADOPTION OF THE SHARE INCENTIVE SCHEME

The Board has resolved to propose the adoption of the Share Incentive Scheme at the Board meeting held on April 29, 2026, to promote its long-term sustainable development, attract and retain Eligible Participants who have contributed to the long-term growth and success of the Group, align the incentives of recipients, Shareholders and the Company and optimize the incentive structure of the Company. The grant of the Restricted Share Units and the Options shall be satisfied by (i) H Shares to be purchased by the Trustee on the secondary market; (ii) new H Shares to be issued by the Company; and (iii) treasury shares legally held by the Company (if any).

The adoption of the Share Incentive Scheme is subject to the fulfilment of the following conditions:

(i) the passing of a special resolution by the Shareholders at the AGM or an EGM to approve and adopt the Share Incentive Scheme; and

(ii) the listing committee of the Stock Exchange granting approval of the listing of, and permission to deal in, any H Shares which may be allotted and issued in respect of the Restricted Share Units and Options to be granted under the Share Incentive Scheme.

Pursuant to Chapter 17 of the Listing Rules, the Share Incentive Scheme will constitute a share scheme of the Company involving the issue of new H Shares and therefore the adoption of the Share Incentive Scheme is subject to the approval of the Shareholders. In accordance with Rule 10.08 of the Listing Rules, no new H Shares will be issued under the Share Incentive Scheme during the six months from March 30, 2026, the date on which the H Shares were listed and on which dealings in the H Shares were first permitted to commence on the Stock Exchange.

The Company will convene its annual general meeting or an extraordinary general meeting, as the case may be, to seek Shareholders' approval for the adoption of the Share Incentive Scheme and related matters. A circular containing a notice of the AGM or the EGM (as applicable), including among other matters, details of the proposed adoption of the Share Incentive Scheme and related matters, will be published as soon as practicable.

As at the date of this announcement, the proposed adoption of the Share Incentive Scheme is subject to the approval of the Shareholders. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's securities.

DEFINITIONS

Unless otherwise specified, the following terms have the following meanings in this announcement:

"AGM"	the annual general meeting of the Company to be convened and held in around June 2026
"Board"	the board of Directors
"Company"	Hangzhou Diagens Biotechnology Co., Ltd. (杭州德適生物科技股份有限公司), a company established under the laws of the PRC as a limited liability company on September 19, 2016 and converted into a joint stock company with limited liability in the PRC on May 7, 2025
"Director(s)"	the Director(s) of the Company
"EGM"	the extraordinary general meeting to be held by the Company for the purpose of considering and, if thought fit, approving, among others, the Share Incentive Scheme
"Eligible Participant(s)"	in respect of the Share Incentive Scheme, (i) the Directors, senior management and key employees of the Company and its subsidiaries; and (ii) independent third parties who provide professional, consulting and other similar services to the Company and its subsidiaries, but excluding (A) placing agents; (B) financial advisers providing advisory services in respect of fundraising, mergers or acquisitions; and (C) professional service providers who provide assurance services or are required to perform services with impartiality and objectivity, such as auditors or valuers
"Group"	the Company and its subsidiaries
"H Share(s)"	ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which is/are listed on the Main Board of the Stock Exchange and subscribed for and traded in Hong Kong dollars
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange
"Main Board"	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with GEM of the Stock Exchange
"Options"	the share option(s) to be granted under the Share Incentive Scheme

"PRC"	the People's Republic of China, excluding, for the purposes of this announcement only, Hong Kong, Macau Special Administrative Region of the People's Republic of China and Taiwan
"Restricted Share Units"	the restricted share unit(s) to be granted under the Share Incentive Scheme
"RMB"	Renminbi, the lawful currency of the PRC
"Shareholder(s)"	shareholder(s) of the H Share(s)
"Share Incentive Scheme"	the share incentive scheme for the Eligible Participants proposed to be adopted at the AGM or an EGM
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"treasury shares"	has the meaning ascribed to it in the Listing Rules
"Trust"	the trust established for the purpose of administering the Share Incentive Scheme
"Trustee"	trustee of the Trust

By order of the Board
Hangzhou Diagens Biotechnology Co., Ltd.
Song Ning
Chairman of the Board and Executive Director

Hangzhou, the PRC, April 29, 2026

As at the date of this announcement, the Board comprises: (i) Dr. Song Ning and Mr. Weng Chih-Hsin (alias Robin Weng) as executive Directors; (ii) Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang Zehao as non-executive Directors; and (iii) Mr. Cha Yang (alias Stanley Cha), Ms. Zhang Jing and Mr. Wang Kaifeng as independent non-executive Directors.